Compound ID | 420
Synonym(s): CB-182561
Class: Lipopeptide
| Agent Type: | Natural product; |
| Spectrum of activity: | Gram-positive |
| Mechanism of action: | Membrane-active agent. Cell wall modulator |
| Target Pathogen: | Active against Streptococcus pneumoniae |
| Description: | Natural product from Streptomyces fradiae whose A54145 lipopeptide biosynthetic gene cluster is engineered to produce recombinant/hybrid lipopeptide; Cubist was searching for a compound that had similar activity as daptomcyin and it's analogue A54145E against Streptococcus pneumoniae but without the issues of being inhibited by surfactant and toxicity respectively |
| Institute where first reported: | Cubist Pharmaceuticals (Merck & Co, USA) |
| Year first mentioned: | 2008 |
| Development status: | Experimental |
| Reason dropped: | Was not as potent as vancomycin in mouse model of pneumonia |
| External links: | |
| PubChem link: | https://pubchem.ncbi.nlm.nih.gov/compound/52942327 |
| Citations: |
|